- CEO
- Jia Le He
- Full Time Employees
- 8,938
- Sector
- Retail trade
- Industry
- Drugstore chains
- Address
- Hefei China
- IPO Date
- Mar 1, 2023
- Business
- Anhui Huaren Health Pharmaceutical Co., Ltd. is a China-based integrated healthcare enterprise primarily engaged in pharmaceutical retail, commercial agency distribution, terminal collective procurement, and pharmaceutical research, development, and manufacturing. Founded in 2001 and headquartered in Hefei, Anhui Province, the company operates an integrated business structure covering the upstream manufacturing, midstream distribution, and downstream retail segments of the pharmaceutical supply chain.
The company operates through four principal business segments: Pharmaceutical Retail, Pharmaceutical Agency and Marketing, Terminal Collective Procurement, and Pharmaceutical Manufacturing and R&D. In its Pharmaceutical Retail segment, the company operates a network of directly managed retail pharmacy chains, primarily under its flagship brand Guosheng Pharmacy (Guosheng Big Pharmacy), dispensing and retailing prescription drugs; over-the-counter (OTC) medicines; traditional Chinese medicinal herbs and prepared slices; medical devices and home healthcare equipment; personal care items; and nutritional supplements. In its Pharmaceutical Agency and Marketing segment, the company serves as a nationwide marketing and commercial distribution agent for upstream pharmaceutical manufacturers, supplying proprietary and licensed drug formulations to regional pharmacy chains, medical clinics, and commercial distributors. In its Terminal Collective Procurement segment, operated primarily through its subsidiary Quanfang Pharmacy, the company provides small-to-medium retail pharmacy chains and independent drugstores with centralized drug purchasing platforms; third-party logistics and wholesale fulfillment; digital supply chain management; and retail operational enablement services. In its Pharmaceutical Manufacturing and R&D segment, operated through subsidiaries including Jiangsu Shenhua Pharmaceutical Co., Ltd. and Zhengyao Technology, the company researches, produces, and markets active pharmaceutical ingredients (APIs); medicinal fungal biotechnology formulations; chemical synthetic preparations; traditional Chinese patent medicines; and health food products.
Geographically, the company concentrates its retail store footprint in East China, maintaining deep market penetration across Anhui Province and actively expanding into Jiangsu, Zhejiang, and Fujian provinces, while its pharmaceutical agency, wholesale distribution, and collective procurement platforms serve institutional clients throughout mainland China.
In recent corporate developments, Anhui Huaren Health Pharmaceutical Co., Ltd. has executed an aggressive regional expansion and supply-chain integration strategy following its initial public offering on the Shenzhen Stock Exchange ChiNext board. To expand its geographic retail network outside Anhui Province, the company has completed several equity acquisitions of regional drugstore operators across East China, including acquiring controlling stakes in Zhoushan Riken Pharmaceutical Chain Co., Ltd., Ma'anshan Mandixin Pharmacy, Fujian Yangzu Huimin, Fujian Haihua Pharmaceutical, and Hangzhou Guosheng Pharmacy, while consolidating manufacturing capabilities through the acquisition of Jiangsu Shenhua Pharmaceutical Co., Ltd. Strategically shifting from retail-focused store expansion toward full-chain vertical integration, the company has initiated private placement financing programs to invest in the construction of automated sorting and intelligent logistics distribution centers, drug research and development platforms, and enterprise digitalization systems.